Entities / Company
Verastem Oncology.
Pharmaceutical company in Masachussets, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 26
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
A study partnered with GenFleet, conducted in China, had its data presented in Barcelona on August 14, 2025, involving Verastem Oncology.Some support1 report
-
Verastem Oncology received FDA approval for its combination therapy and published the trial results in the journal JCO.Some support2 reports1 development inside
-
Verastem Oncology announced a clinical trial in Boston.Speculative1 report
-
Verastem Oncology began using LinkedIn for company presence on July 8, 2025.Speculative1 report
-
Immuneering is testing an approach that slows cancer down.Speculative1 report
-
Verastem Oncology, led by Ras, began using LinkedIn on August 27, 2025, to share updates about its medicines targeting RAS/MAPK pathway-driven cancers.Some support3 reports
-
Verastem Oncology shares increased by 10.6% on August 8, 2025, compared to the S&P 500's 7.9% gain.Some support2 reports
-
FDA approved AVMAPKI FAKZYNJA CO-PACK treatment by Verastem Oncology.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Verastem Oncology this week
News at the entities that move Verastem Oncology most-
FDA StructuralFDA conducted surprise raids and inspections in Bihar state, directed by state government officials.Moves Verastem Oncology
-
Royal Bank of Canada Mentioned togetherRoyal Bank of Canada dropped its price objective for Crown Castle Inc., while Citigroup reiterated an outperform rating.Moves Verastem Oncology
-
LinkedIn Shared contextTzelios used a LinkedIn profile associated with Douglas Elliman.Moves Verastem Oncology
-
Boston Shared contextA Conservancy includes officials from Boston and Brookline in a recent development.Moves Verastem Oncology
Connections
The 5 strongest of 26, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
FDA formally regulates and approves combination therapies developed by Verastem Oncology.
-
LinkedIn Shared context
Verastem Oncology utilizes LinkedIn as a platform for company communication and updates.
-
Boston Shared context
Verastem Oncology conducts its operations and announcements within the geographic context of Boston.
-
Ras Shared context
The entities share a contextual focus on developing medicines for RAS/MAPK pathway-driven cancers.
-
Royal Bank of Canada Mentioned together
RBC provides financial ratings and target prices for Verastem Oncology.
History
Events by the month they beganAugust 2026
1 eventJune 2026
8 events- A study partnered with GenFleet, conducted in China, had its data presented in Barcelona on August 14, 2025, involving Verastem Oncology.
- Verastem Oncology received FDA approval for its combination therapy and published the trial results in the journal JCO.
- Verastem Oncology announced a clinical trial in Boston.
- Verastem Oncology began using LinkedIn for company presence on July 8, 2025.
- Immuneering is testing an approach that slows cancer down.
- Verastem Oncology, led by Ras, began using LinkedIn on August 27, 2025, to share updates about its medicines targeting RAS/MAPK pathway-driven cancers.
- Verastem Oncology shares increased by 10.6% on August 8, 2025, compared to the S&P 500's 7.9% gain.
- FDA approved AVMAPKI FAKZYNJA CO-PACK treatment by Verastem Oncology.